Drug Profile
Research programme: tetrahydrofolate dehydrogenase inhibitors - Cloud Pharmaceuticals
Alternative Names: Anti-parasitic therapeutics - Cloud Pharmaceuticals; DHFR inhibitors - Cloud Pharmaceuticals; Dihydrofolate reductase inhibtors - Cloud Pharmaceuticals; pfDHFR inhibtor - Cloud PharmaceuticalsLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Cloud Pharmaceuticals
- Class
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Malaria in USA
- 14 Jul 2014 Early research in Malaria in USA (unspecified route)